Immunome Inc.是一家从事生物药品研发的公司,股票今日盘中大涨5.1%,引起了市场的广泛关注。
据悉,公司正继续加强其临床前和临床资产管线,包括IM-1021(一种针对成纤维细胞激活蛋白的抗体)和IM-4320等产品。公司以肿瘤学和传染病为重点领域,期望通过这些管线产品进一步改变疾病治疗方式。
Immunome拥有专利人体记忆B细胞平台,有望从中发掘出一流的创新疗法。凭借这些积极的研发动向,投资者对公司的长期前景重拾信心,推动股价出现显著上涨走势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.